Short-bowel syndrome - surgical treatment with long-term benefit?

Heeckt, P. F.; Klein, Delphine; Beger, H. G.

doi:10.1007/s004230050011

Cited by 8 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three observers who were blinded to the clinical information evaluated the immunohistochemical staining scores independently. Staining intensity was graded semi-quantitatively using the H-SCORE [11], which was calculated using the following equation: H-SCORE = ∑Pi (i + 1), where i is the intensity of staining with a value of 1, 2 or 3 (mild, moderate, or strong, respectively) and Pi is the percentage of epithelial cells stained with different intensity, varying from 0% to 100%. The results are expressed as the mean ± SE.…”

Section: Methodsmentioning

confidence: 99%

Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine

Zhang

Xiao

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundBerberine is known to improve glucose and lipid metabolism disorders, but it poorly absorbed into the blood stream from the gut. Therefore, the exact underlying mechanism for berberine is still unknown. In this study, we investigated the effect of berberine on glucose metabolism in diabetic rats and tested the hypothesis that berberine acts directly in the terminal ileums.MethodsRats were divided into a control group, diabetic group (DM), low dose of berberine group (BerL) and high dose of berberine group (BerH). Ileum samples were analyzed using a Roche NimbleGen mRNA array, qPCR and immunohistochemistry.ResultsWe found that 8 weeks of treatment with berberine significantly decreased fasting blood glucose levels. An oral glucose tolerance test (OGTT) showed that blood glucose was significantly reduced in the BerL and BerH groups before and at 30 min, 60 min and 120 min after oral glucose administration. Plasma postprandial glucagon-like peptide-1 (GLP-1) levels were increased in the berberine-treated groups. The ileum from the BerH group had 2112 genes with significantly changed expression (780 increased, 1332 decreased). KEGG pathway analyses indicated that all differentially expressed genes included 9 KEGG pathways. The top two pathways were the MAPK signaling pathway and the GnRH signaling pathway. Q-RT-PCR and immunohistochemistry verified that glucagon-like peptide 1 receptor (Glp1r) and mitogen activated protein kinase 10 (Mapk10) were significantly up-regulated, in contrast, gonadotropin releasing hormone receptor (Gnrhr) and gonadotropin-releasing hormone 1 (Gnrh1) were down-regulated in the BerH group.ConclusionOur data suggest that berberine can improve blood glucose levels in diabetic rats. The mechanisms involved may be in the MAPK and GnRh-Glp-1 pathways in the ileum.

show abstract

Section: Methodsmentioning

confidence: 99%

Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine

Zhang

Xiao

et al. 2014

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Three observers blinded to the clinical information evaluated the immunohistochemical staining scores independently. Staining intensity was graded semi-quantitatively using the H-SCORE [15] which was calculated using the following equation: H-SCORE = ∑Pi (i +1), where i is the intensity of staining with a value of 1, 2 or 3 (mild, moderate, or strong, respectively) and Pi is the percentage of epithelial cells stained with different intensity, varying from 0% to 100%. The results are expressed as the mean ± SE.…”

Section: Methodsmentioning

confidence: 99%

Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats

Zhang

Xiao

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are non-coding RNA molecules involved in the post-transcriptional regulation of a large number of genes, including those involved in glucose metabolism. Acarbose is an α-glucosidase inhibitor that improves glycemic control by decreasing the intestinal absorption of glucose, thereby decreasing the elevation of postprandial blood glucose. However, acarbose is poorly absorbed into the blood stream from the gut. Therefore, the exact mechanisms by which acarbose affects glucose metabolism are unclear. This study investigated the effect of acarbose on glucose metabolism in diabetic rats and tested the hypothesis that acarbose acts directly through miRNA-regulated expression in the intestinal epithelium. Rats were divided into four groups: a control group, a diabetic group (DM), a low dose of acarbose group (AcarL) and a high dose of acarbose group (AcarH). Ileum samples were analyzed using miRCURY LNA™ microRNA Array, qPCR and immunohistochemistry. We found that 8-week treatment with acarbose significantly decreased fasting blood glucose. Oral glucose tolerance tests (OGTT) showed that blood glucose was significantly reduced in the AcarL and AcarH groups at 30 min, 60 min and 120 min after oral glucose administration. We found that miR-151*, miR-10a-5p, miR-205, miR-17-5p, miR-145 and miR-664 were up-regulated in the AcarH group, while miR-541 and miR-135b were down-regulated. Through target gene analysis, real time PCR and immunohistochemistry verification, we found that these miRNAs suppressed the expression of proinflammatory cytokines [IL6 (interleukin 6) and TNF (tumor necrosis factor)] and mitogen activated protein kinase 1 (MAPK1). Our data suggest that acarbose can improve blood glucose in diabetic rats through the MAPK pathway and can down-regulate proinflammatory factors by activating miR-10a-5p and miR-664 in the ileum.

show abstract

“…30 If children cannot be weaned from parenteral nutrition through the surgical methods mentioned above, the last therapeutic alternative is small bowel transplantation. 3,5,7,8,[31][32][33][34] However, survival rates of 55% to 60% 3 years after small bowel transplantation. 7,32,34 are not satisfying.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4] However, because of parenteral nutrition and intensive care, children with short bowel syndrome survive, [5][6][7][8] but complications such as sepsis and liver failure are common. [5][6][7][8][9][10][11][12][13][14][15] The aim of our study was to establish a new method for small bowel elongation by means of autologicallotopic ileummucosa transplantation in an animal model. 16 After successful transplantation we evaluated the absorptive capacity of the transplanted ileummucosa in comparison with normal ileummucosa.…”

mentioning

confidence: 99%

Absorption of D(+)-xylose, cobalamin, and folic acid after autologic-allotopic ileummucosa transplantation in beagles

Beiler

Steinorth

Witt

et al. 2004

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Short-bowel syndrome - surgical treatment with long-term benefit?

Cited by 8 publications

References 53 publications

Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine

Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine

Acarbose Reduces Blood Glucose by Activating miR-10a-5p and miR-664 in Diabetic Rats

Absorption of D(+)-xylose, cobalamin, and folic acid after autologic-allotopic ileummucosa transplantation in beagles

Contact Info

Product

Resources

About